Syndax Pharmaceuticals Stock News

Upgrades Tudor Pickering upgraded the previous rating for EQT Corp (NYSE:EQT) from Hold to Buy. EQT earned $0.41 in the fourth quarter, compared to $0.02 in the year-ago quarter. At the moment, the st

Penny stocks can make money. Success stories include Advanced Micro Devices, a former penny stock that earned a $3.2 billion net income in 2021.

Syndax’s lead product candidates include SNDX-5613 and SNDX-6352. Click here to read about its growth prospects and my recommendation.

Today's $19 share quote is backed by as much as $7.50 in cash vs. total liabilities under $1 per unit. Larger drug trials are underway testing the usefulness of two cancer-related products.

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares, rose in value on Friday, 03/11/22, with the stock price down by -3.60% to the previous day’s close as strong demand from buyers drove the stock to $16.85. Actively observing the price movement in the last trading, the stock closed the session at $17.48, falling within a range of $16.84 … Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) Is An Exciting Stock To Watch. Read More »

WALTHAM, Mass., March 4, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that in connection with the hiring, announced on…

Syndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q4 2021 Results - Earnings Call Transcript

The clinical-stage biotech, Syndax Pharmaceuticals (SNDX), announced on Tuesday that Kate Madigan, M.D., will be appointed as the company’s new Chief Medical Officer,…

Syndax Pharmaceuticals press release (SNDX): Q4 GAAP EPS of $1.81 beats by $1.84.Revenue of $126.6M (+63200.0% Y/Y) beats by $67.92M.

WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended…

Syndax Pharmaceuticals (NASDAQ:SNDX) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close.The consensus EPS Estimate is $0.46 (+204.5% Y/Y) and…

WALTHAM, Mass., Feb. 22, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its fourth quarter and

During the last session, Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)s traded shares were 0.55 million, with the beta value of the company hitting 1.57. At the end of the trading day, the stocks price was $16.44, reflecting an intraday gain of 3.98% or $0.63. The 52-week high for the SNDX share is $25.68, that puts it down Is Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) Still A Buy After A 9.75% Weekly Jump? Read More »

Upgrades For Blue Bird Corp (NASDAQ:BLBD), Roth Capital upgraded the previous rating of Neutral to Buy. Blue Bird earned $0.07 in the first quarter, compared to $0.00 in the year-ago quarter. The stoc

Syndax Pharmaceuticals (SNDX) said Michael Metzger, president and COO, will transition to the role of CEO, effective Feb